Back to Search
Start Over
A four-drug standardized short regimen for highly resistant TB in South-West Nigeria.
- Source :
-
International health [Int Health] 2024 Jan 02; Vol. 16 (1), pp. 123-125. - Publication Year :
- 2024
-
Abstract
- Background: Patients with TB resistant to rifampicin (Rr-TB), and those with additional resistance to fluoroquinolones (pre-XDR-TB), should be treated with bedaquiline-pretomanid-linezolid-moxifloxacin and bedaquiline-pretomanid-linezolid, respectively. However, pretomanid is not yet widely available.<br />Methods: This is a pragmatic prospective single-arm study investigating the efficacy and safety of 9 mo of bedaquiline-delamanid-linezolid-clofazimine in patients with pre-XDR-TB or Rr-TB unresponsive to Rr-TB treatment in Nigeria.<br />Results: From January 2020 to June 2022, 14 of 20 patients (70%) successfully completed treatment, five died and one was lost-to-follow-up. No one experienced a treatment-emergent grade three/four event. Treatment success was higher compared with global pre-XDR-TB treatment outcomes.<br />Conclusions: While pretomanid is unavailable, highly resistant TB can be treated with bedaquiline-delamanid-linezolid-clofazimine.<br /> (© The Author(s) 2023. Published by Oxford University Press on behalf of Royal Society of Tropical Medicine and Hygiene.)
Details
- Language :
- English
- ISSN :
- 1876-3405
- Volume :
- 16
- Issue :
- 1
- Database :
- MEDLINE
- Journal :
- International health
- Publication Type :
- Academic Journal
- Accession number :
- 37026448
- Full Text :
- https://doi.org/10.1093/inthealth/ihad023